ENDRA Life Sciences logo
NDRAENDRA Life Sciences
Trade NDRA now
ENDRA Life Sciences primary media

About ENDRA Life Sciences

ENDRA Life Sciences (NASDAQ:NDRA) is a pioneering company focused on enhancing the capabilities of ultrasound technology to solve complex health problems. At its core, ENDRA aims to develop and commercialize Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to provide clinicians with the ability to visualize tissue function and composition in ways previously possible only with CT or MRI, but at a fraction of the cost and with portability. This innovative approach opens new possibilities in diagnosing and monitoring diseases by making high-quality imaging more accessible and convenient. With projects spanning from early-stage clinical trials to partnerships aimed at integrating TAEUS into existing medical imaging workflows, ENDRA's objective is clear: to improve global health by making advanced imaging technology more affordable and widespread.

What is NDRA known for?

Snapshot

Public US
Ownership
2008
Year founded
21
Employees
Ann Arbor, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Ann Arbor, US

Products and/or services of ENDRA Life Sciences

  • Development of TAEUS technology to assess non-alcoholic fatty liver disease (NAFLD) via ultrasound, providing a non-invasive, cost-effective diagnostic tool.
  • Research into expanding TAEUS applications beyond NAFLD, targeting liver disease diagnostics and potentially other organ assessment.
  • Partnerships with medical institutions and liver centers to conduct clinical studies, enhancing TAEUS validation and adoption.
  • Collaboration with healthcare and technology companies to integrate TAEUS technology into existing ultrasound systems, broadening market reach.
  • Efforts to secure regulatory approvals in key global markets, ensuring TAEUS meets international healthcare standards and requirements.
  • Outreach and educational programs for healthcare professionals to increase awareness and understanding of TAEUS technology, supporting its clinical uptake.

ENDRA Life Sciences executive team

  • Mr. Alexander Y. TokmanCEO & Chairman
  • Mr. Richard JacrouxCFO & Secretary
  • Dr. Jonathan Behr Ph.D.Co-Founder
  • Mr. Scott SoberHead of Operations
  • Mr. Ziad RouagHead of Regulatory & Clinical Affairs
  • Mr. Idan SteinbergHead of Engineering

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.